Peer-influenced content. Sources you trust. No registration required. This is HCN.

Cancer Therapy AdvisorT-VEC Demonstrates Long-Term Efficacy in High-Risk Melanoma

Phase 2 Trial Reveals Superior Relapse-Free and Overall Survival Rates with T-VEC

A recent study in JAMA Oncology has shed light on the potential benefits of administering talimogene laherparepvec (T-VEC) before surgical intervention in patients with advanced melanoma. The findings indicate a significant improvement in long-term survival metrics compared to surgery alone.

HCN Medical Memo
These findings underscore the potential of T-VEC as a neoadjuvant treatment in improving long-term outcomes for advanced melanoma patients. The data suggests that incorporating T-VEC into the treatment regimen could offer a significant survival advantage, making it a subject worthy of further investigation and possibly altering future treatment protocols.

Key Points
  • The study was a phase 2 trial involving 150 patients with stage IIIB-IVM1a melanoma.
  • Patients treated with T-VEC before surgery had a 5-year relapse-free survival (RFS) rate of 22.3%, compared to 15.2% in the surgery-alone group.
  • The 5-year overall survival rate was 77.3% in the T-VEC group and 62.7% in the surgery-alone group.
  • Distant metastasis-free survival was notably better in the T-VEC arm (HR, 0.73; 80% CI, 0.57-0.94).
  • Researchers advocate for further studies combining T-VEC with checkpoint inhibitors for high-risk melanoma.

“These results support further investigation of neoadjuvant T-VEC combined with checkpoint inhibitors for the treatment of resectable high-risk melanoma.”
– Dummer R, Gyorki DE, Hyngstrom JR, et al (Researchers)

Additional Points
  • Patients in the T-VEC arm received six intralesional injections prior to surgery.
  • Adjuvant therapy was more commonly administered in the surgery-alone group (31.9% vs. 13.7% in the T-VEC group).
  • The median follow-up for the study was 63.3 months.

More on Melanoma

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form